Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer

NCT01208051 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01208051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
September 9, 2010
Completion date
February 1, 2020
Enrollment
127 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

refractory differentiated thyroid gland carcinoma, refractory thyroid gland follicular carcinoma, refractory thyroid gland hurthle cell carcinoma, refractory thyroid gland papillary carcinoma, unresectable thyroid gland carcinoma